111 filings
Page 3 of 6
8-K
3uje8x7u2
18 Oct 21
Zai Lab Appoints Scott Morrison
7:38am
8-K
nm6kkulelmes3p
9 Aug 21
Zai Lab Announces Second Quarter 2021
4:06pm
8-K
dqdssx19z
24 Jun 21
Amendments to Articles of Incorporation or Bylaws
4:01pm
8-K
85oi32j4rb66twhb
16 Jun 21
Zai Lab and MacroGenics Enter Into Broad Strategic
7:43am
8-K
gbdmiwfq
1 Jun 21
Entry into a Material Definitive Agreement
7:30am
8-K
50t6uf4i3yu
10 May 21
Zai Lab Reports First Quarter 2021 Financial Results
8:55am
8-K
kqo5s 5o57mla8878
23 Apr 21
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
12:29pm
8-K
2gof5dlv6r0 j1t
21 Apr 21
Financial Statements and Exhibits
3:00pm
8-K
ed6fkis92ibp6geu
20 Apr 21
Zai Lab Announces Pricing of Public Offering of American Depositary Shares and Ordinary Shares
9:38pm
8-K
a9w9 eiwr
19 Apr 21
Zai Lab Announces Proposed Public Offering of American Depositary Shares
4:30pm
8-K
hx10zo6m
13 Apr 21
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
7:45am
8-K
8xo2uztt
31 Mar 21
China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal
7:32am
8-K
j7x1m6ox 88
1 Mar 21
Zai Lab Announces Financial Results
7:01am
8-K
31jp2xo bphv5a6bw5hm
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
47fktw7edwn7pfepo
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
8-K
uuwy93
4 Jan 21
Other Events
7:27am
6-K
42h248m6n
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
njd90s6f99r3hl9q4nu
28 Dec 20
Zai Lab and Cullinan Oncology Announce Strategic
7:30am
6-K
nrjn1g
1 Dec 20
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
7:30am
6-K
urawcp8t xzwv6vz6
22 Oct 20
Current report (foreign)
8:03am